0001654954-21-004560.txt : 20210525 0001654954-21-004560.hdr.sgml : 20210525 20210423120412 ACCESSION NUMBER: 0001654954-21-004560 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9350 WILSHIRE BLVD. STREET 2: SUITE 203 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 9350 WILSHIRE BLVD. STREET 2: SUITE 203 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 CORRESP 1 filename1.htm gtbp_corresp
GT BIOPHARMA, INC.
9350 Wilshire Blvd.
Suite 203
Beverly Hills, CA 90212
April 23, 2021
 
Via EDGAR Submission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
 
Attention:   Chris Edwards
 
Re: 
GT Biopharma, Inc.
Registration Statement on Form S-1
CIK No. 0000109657
SEC Registration No. 333-255429
 
Ladies and Gentlemen:
 
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-255429) (the “Registration Statement”) of GT Biopharma, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on April 27, 2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Baker & McKenzie LLP by calling Roger Bivans at (214) 978-3095.
 
Thank you for your assistance with this matter.
 
Very truly yours,
 
/s/ Michael Handelman
 
Michael Handelman
Chief Financial Officer
Click here to enter Sender1 Email Address.